

FIG. 1






FIG. 2










FIG. 5








FIG. 8




FIG. 9

| The state of the last |                  |
|-----------------------|------------------|
|                       |                  |
| F                     | ,                |
| -                     |                  |
| Kath Kath             | -                |
|                       |                  |
| Ţ                     |                  |
|                       |                  |
| æ                     |                  |
|                       | 45.000           |
|                       | 45.000           |
|                       | through the same |

| 11. YVIEW - EARLYVIEW REPORT (JUL 1999 - JUL 2000) P 50 PRESCRIBERS FOR ROLLING 12M MARKET VOL  KEY PRODUCTS: DRUG#1, DRUG#2  NRX MARKET SHARE (%) NRX JUNYO JULYO   |   |
|--|---|
| 9/15<br>9/15<br>9/15<br>9/15<br>18.2<br>18.2<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19<br>19   |   |
|  | TS<br>ESCRIPTI  |
| SEP'00 SE 099/08 0 09/   | TESCRIBI  |
| SEP'00 SE 099/01 0 09/   | 121<br>OTHER PI   |
| G'00 SEP'00 S<br>8/25 09/01<br>74.6 78.7<br>74.6 78.7<br>76.6 84.3<br>76.6 84.3<br>76.5 51.1   | 15 HRAN   |
| 0 AUG'O<br>0 AUG'O<br>0 AUG'O<br>0 AUG'O<br>10 AUG'O   | SFASTE  |
| 414<br>08/18<br>16.5<br>16.5<br>496<br>496<br>496<br>18.3<br>81.7<br>18.3<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81.7<br>81. | S/DRUG  |
| NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO<br>NOCO     | 21<br>HERAPIE   |
| FARLYVIEW - EARLYVIEW REPORT (JUL 1999 - JUL 2000)  TOP 50 PRESCRIBERS FOR ROLLING 14M MARKET VOL  KEY PRODUCTS: DRUG #1, DRUG#2  NRX MARKET SHARE (%)  1196   | IKT VOL 185 13 18 15 16 8 15 21 17 15 12 16 18 18 18 17 17 15 12 1 16 18 1 18 1 18 1 18 1 18 1 18 1 1 |
| 117VIEW - EARLYVIEW REPORT (JUL 1999 - JUL KEY PRODUCTS: DRUG #1, DRUG#2   ALTON O JUL'00 JUL'00 JUL'00 JUL'00 AUG'00 AUG   | 8<br>AVIOR TO   |
| NEX MA SODUCTS: DRUG #1, DRU BERS FOR ROLLING 12M SODUCTS: DRUG #1, DRU 10, 00 JUL'00 JUL'00 JUL'0 07/07 07/14 07/21 07/2 367 415 415 44  NRX M JUL'00 JUL'00 JUL'00 JUL'0 07/07 07/14 07/21 07/2 9.7 22.2 17.5 19 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 73.2 70.4 82.5 7 74.8 77 7 75.9 83 78.9 7 76.9 83 78.9 7 77.9 83 78.9 7 77.9 83 78.9 7 77.9 83 31 33 78.48 71 75 5 76.6 49.9 61.2 5 56.7 5   | 16  |
| N EARLYVIEW REPORT (- RESCRIBERS FOR ROLLING NOTION JUL'00 JUL  | 15<br>3 SWITCH  |
| VIEW REF<br>VOCTS: DR<br>VOCTS: DR<br>V   | 18 <br>NSTRATIN   |
| JUL'00<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07<br>07/07/07<br>07/07/07/07<br>07/07/07/07/07/07/07/07/07/07/07/07/07/0  | DEMON   |
| JUN'00 JU   | 13<br>AVERAGE   |
| NRX NNX NOL 1196 6345 4594 4594 4594 4594 4594 4594 4594 4   | 185<br>R THAN   |
| G. 10  CHRONIC PAIN  CHRONIC PAIN  275  040001099  CHRONIC PAIN  DRUG #1  ON  WKT VOL  THIS PRESCRIBER IS SHO  DRUG #2  ON  WKT VOL  SLOWLY MAKING DRUG #  ON  WKT VOL  DRUG #2  ON  ON  WKT VOL  DRUG #2  ON  ON  ON  ON  ON  ON  ON  ON  ON  O   | #1 SLOWF  |
| PAIN 402 TREND PAIN N LRX TAKING DRUG N N N STARITS SIGNIF   | N DRUG  |
| GHEONIC PAIN  CHRONIC PAIN  275  040001099  PRODUCT  CHRONIC PAIN  TAIS PRESCRIB  MKT VOL  MKT VOL  DRUG #1  DRUG #2  MKT VOL  MKT VOL  NEW THERAPY STAIN  DRUG #1  DRUG #1  DRUG #2  MKT VOL  NEW THERAPY STAIN  DRUG #1  DRUG #1  DRUG #1  DRUG #1  DRUG #2  MKT VOL  NEW THERAPY STAIN  DRUG #1  DRUG #1  DRUG #1  DRUG #1  DRUG #2   | NG UP OI  |
| FG. 10 CCHRONIC P 275 040001099 - CCHRONIC F 275 040001099 - CCHRONIC F 275 040001099 - PRODUCT DRUG #1 DRUG #1 DRUG #2 MKT VOL MKT VOL MKT VOL MKT VOL MKT VOL SLOWLY MM SLOWLY MM SLOWLY MM DRUG #2  MKT VOL   | MKT VOL<br>TITRATING  |
|  | 8   |
| 410  MARKET SALES FORCE TERRITORY EARLYVIEW SUMMARY EARLYVIEW SUMMARY A20a MARKET SALES FORCE TERRITORY PRESCRIBER A20a DOE, JOHN 5240583058 (21) 34 DENNY DRIVE CALYPSO MA 02150 A220583012 (4) 5240583012 (4) 5240583012 (4) 5240583012 (4) 5240583012 (1) 34 DENNY DRIVE CALYPSO MA 02150 MA 02180 MARTIN, MIKE   | VENUE<br>422d   |
| MARKET SALES FORCE TERRITORY EARLYVIEW SU EARLYVIEW SU EARLYVIEW SU ANARKET SALES FORCE TERRITORY PRESCRIBER DOE, JOHN DOE, JOHN DOE, JOHN CALYPSO MA 02150 MA 02180  | 2 RANCH AV<br>SUDBURY<br>MA 01776   |
| MARKET SALES FOR TERRITORY EARLYVIEW EARLYVIEW EARLYVIEW EARLYVIEW TERRITORY TERRITORY PRESCRIBE S24058305 34 DENNY I CALYPSO MA 02150 MA 02150 MA 02150 INTERNAL TERRITORY ADAMS, JC ADAM   | 2 RANCH<br>SUDBURY<br>MA 01776  |
| 420 Cbb Cba C C C C C C C C C C C C C C C C  |   |